{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:00:34Z","timestamp":1753884034187,"version":"3.41.2"},"reference-count":65,"publisher":"The Company of Biologists","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"am","delay-in-days":503,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fund for Research training in Industry and Agriculture"},{"name":"Fund of Scientific Research \u2013 Fonds National de la Recherche Scientifique (FSR-FNRS)\u00a0"},{"DOI":"10.13039\/501100017653","name":"Fonds Sp\u00e9ciaux de Recherche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds de la Recherche Scientifique M\u00e9dicale (FRSM), Fonds Sp\u00e9ciaux de Recherche"},{"name":"Foundation St Luc"},{"DOI":"10.13039\/100000897","name":"Belgian Cystic Fibrosis Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Cystic fibrosis (CF) is a genetic disease characterized by progressive lung and chronic digestive manifestations. We have shown that therapeutic doses of vardenafil, a phosphodiesterase type 5 (PDE5) inhibitor, corrects CF Transmembrane conductance Regulator (CFTR)-dependent chloride transport in respiratory and intestinal tissues of F508del homozygous mice. Here, we studied the effect of vardenafil on CFTR in 16HBE14o\u2212 and CFBE41o\u2212 cell lines. First, the expression levels of PDE5 mRNA in these cell lines were monitored. The two cell lines were exposed to different drugs (dimethyl sulfoxide, 8-Br-cGMP, forskolin, or vardenafil). The cAMP and cGMP intracellular concentrations were measured. Finally, we localized the CFTR by immunolabelling. PDE5 was similarly expressed in both wild-type and in CF cells. A fast and transient rise in cGMP intracellular contents followed treatment with vardenafil, confirming its PDE5 inhibitory effect. We showed that vardenafil promoted both the early steps of the cellular processing and the trafficking of F508del without fully addressing the protein to the plasma membrane. The effect was not reproduced by the brominated cGMP analogue and it was not prevented by the combination of a protein kinase G (PKG) inhibitor and vardenafil. These findings support the view that vardenafil partially rescues F508del through cGMP\/PKG-independent mechanisms.<\/jats:p>","DOI":"10.1242\/bio.053116","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T13:27:56Z","timestamp":1596461276000},"source":"Crossref","is-referenced-by-count":1,"title":["Vardenafil increases intracellular accumulation of the most prevalent mutant CFTR in human bronchial epithelial cells"],"prefix":"10.1242","author":[{"given":"Barbara","family":"Dhooghe","sequence":"first","affiliation":[{"name":"Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 catholique de Louvain, Brussels - Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0694-1947","authenticated-orcid":false,"given":"Caroline","family":"Bouzin","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cell imaging platform, Universit\u00e9 catholique de Louvain, Brussels - Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3343-8872","authenticated-orcid":false,"given":"Ang\u00e9lique","family":"Mottais","sequence":"additional","affiliation":[{"name":"Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 catholique de Louvain, Brussels - Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8589-3279","authenticated-orcid":false,"given":"Emmanuel","family":"Hermans","sequence":"additional","affiliation":[{"name":"Institute of Neurosciences, Facult\u00e9 de Pharmacie et Sciences Biom\u00e9dicales, Universit\u00e9 catholique de Louvain, Brussels - Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4806-9803","authenticated-orcid":false,"given":"Martial","family":"Delion","sequence":"additional","affiliation":[{"name":"Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 catholique de Louvain, Brussels - Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadtha","family":"Panin","sequence":"additional","affiliation":[{"name":"Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 catholique de Louvain, Brussels - Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Noel","sequence":"additional","affiliation":[{"name":"Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 catholique de Louvain, Brussels - Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-3413","authenticated-orcid":false,"given":"Teresinha","family":"Leal","sequence":"additional","affiliation":[{"name":"Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 catholique de Louvain, Brussels - Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"237","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"key":"2021042700290910900_BIO053116C1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jcf.2019.04.014","article-title":"CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials","volume":"18","author":"Bell","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"2021042700290910900_BIO053116C2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1124\/jpet.114.214890","article-title":"Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing","volume":"350","author":"Boinot","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021042700290910900_BIO053116C3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med."},{"key":"2021042700290910900_BIO053116C4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1530\/acta.0.1070225","article-title":"Forskolin perturbs cGMP as well as cAMP levels in human thyroid cells","volume":"107","author":"Brandi","year":"1984","journal-title":"Acta Endocrinol."},{"key":"2021042700290910900_BIO053116C5","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"2021042700290910900_BIO053116C6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/cbic.200700027","article-title":"Correctors of protein trafficking defects identified by a novel high-throughput screening assay","volume":"8","author":"Carlile","year":"2007","journal-title":"Chembiochem"},{"key":"2021042700290910900_BIO053116C7","doi-asserted-by":"crossref","first-page":"11304","DOI":"10.1016\/S0021-9258(18)82125-1","article-title":"Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites","volume":"268","author":"Chang","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2021042700290910900_BIO053116C8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","article-title":"Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis","volume":"63","author":"Cheng","year":"1990","journal-title":"Cell"},{"key":"2021042700290910900_BIO053116C9","doi-asserted-by":"publisher","first-page":"246ra96","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2021042700290910900_BIO053116C10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/23808993.2016.1175299","article-title":"Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation","volume":"1","author":"Cholon","year":"2016","journal-title":"Expert Rev. Precis Med. Drug Dev."},{"key":"2021042700290910900_BIO053116C11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"key":"2021042700290910900_BIO053116C12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0304-4165(80)90063-X","article-title":"Characteristics of a new binding protein distinct from the kinase for guanosine 3\u2032:5\u2032-monophosphate in rat platelets","volume":"631","author":"Coquil","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl. 1","key":"2021042700290910900_BIO053116C13","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/sj.ijir.3901205","article-title":"Mechanisms of action of PDE5 inhibition in erectile dysfunction","volume":"16","author":"Corbin","year":"2004","journal-title":"Int. J. Impot. Res."},{"key":"2021042700290910900_BIO053116C14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00424-015-1758-5","article-title":"Anoctamin 1 (Ano1) is required for glucose-induced membrane potential oscillations and insulin secretion by murine \u03b2-cells","volume":"468","author":"Crutzen","year":"2016","journal-title":"Pflugers Arch."},{"key":"2021042700290910900_BIO053116C15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021042700290910900_BIO053116C16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med."},{"key":"2021042700290910900_BIO053116C17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"2021042700290910900_BIO053116C18","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1101\/gr.GR-1649R","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res."},{"key":"2021042700290910900_BIO053116C19","doi-asserted-by":"publisher","first-page":"e77314","DOI":"10.1371\/journal.pone.0077314","article-title":"Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice","volume":"8","author":"Dhooghe","year":"2013","journal-title":"PLoS ONE"},{"key":"2021042700290910900_BIO053116C20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1517\/13543784.2016.1154041","article-title":"Strategies in early clinical development for the treatment of basic defects of cystic fibrosis","volume":"25","author":"Dhooghe","year":"2016","journal-title":"Expert Opin Investig. Drugs"},{"key":"2021042700290910900_BIO053116C21","doi-asserted-by":"publisher","first-page":"e19329","DOI":"10.1371\/journal.pone.0019329","article-title":"The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1\/P-glycoprotein transporter","volume":"6","author":"Ding","year":"2011","journal-title":"PLoS ONE"},{"key":"2021042700290910900_BIO053116C22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/thx.2003.019778","article-title":"Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis","volume":"60","author":"Dormer","year":"2005","journal-title":"Thorax"},{"key":"2021042700290910900_BIO053116C23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00441-005-0062-7","article-title":"Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-","volume":"323","author":"Ehrhardt","year":"2006","journal-title":"Cell Tissue Res."},{"key":"2021042700290910900_BIO053116C24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.chembiol.2013.06.004","article-title":"Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction","volume":"20","author":"Farinha","year":"2013","journal-title":"Chem. Biol."},{"key":"2021042700290910900_BIO053116C25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/0076-6879(88)59067-5","article-title":"Purification of cGMP-binding protein phosphodiesterase from rat lung","volume":"159","author":"Francis","year":"1988","journal-title":"Meth. Enzymol."},{"key":"2021042700290910900_BIO053116C26","doi-asserted-by":"publisher","first-page":"26626","DOI":"10.1074\/jbc.270.44.26626","article-title":"Isotype-specific activation of cystic fibrosis transmembrane conductance regulator-chloride channels by cGMP-dependent protein kinase II","volume":"270","author":"French","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2021042700290910900_BIO053116C27","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1091\/mbc.e04-03-0176","article-title":"Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator","volume":"15","author":"Gentzsch","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"2021042700290910900_BIO053116C28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/sj.bjp.0706353","article-title":"The role of epithelial P2Y2 and P2Y4 receptors in the regulation of intestinal chloride secretion","volume":"146","author":"Ghanem","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"2021042700290910900_BIO053116C29","doi-asserted-by":"publisher","first-page":"C708","DOI":"10.1152\/ajpcell.00544.2004","article-title":"STa and cGMP stimulate CFTR translocation to the surface of villus enterocytes in rat jejunum and is regulated by protein kinase G","volume":"289","author":"Golin-Bisello","year":"2005","journal-title":"Am. J. Physiol., Cell Physiol."},{"key":"2021042700290910900_BIO053116C30","first-page":"435","article-title":"Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature","volume":"7","author":"Gresser","year":"2002","journal-title":"Eur. J. Med. Res."},{"issue":"Suppl. 2","key":"2021042700290910900_BIO053116C31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jcf.2004.05.040","article-title":"Established cell lines used in cystic fibrosis research","volume":"3","author":"Gruenert","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"2021042700290910900_BIO053116C32","first-page":"281","article-title":"Cyclic GMP binding and cyclic GMP phosphodiesterase in rat platelets","volume":"4","author":"Hamet","year":"1978","journal-title":"J. Cyclic Nucleotide Res."},{"key":"2021042700290910900_BIO053116C33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1586\/14779072.4.3.293","article-title":"Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension","volume":"4","author":"Hemnes","year":"2006","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"2021042700290910900_BIO053116C34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0014-5793(89)80625-8","article-title":"Forskolin stimulates pinealocyte cGMP accumulation. Dramatic potentiation by an alpha 1-adrenergic----[Ca2+]i mechanism involving protein kinase C","volume":"249","author":"Ho","year":"1989","journal-title":"FEBS Lett."},{"key":"2021042700290910900_BIO053116C35","doi-asserted-by":"publisher","first-page":"e64341","DOI":"10.1371\/journal.pone.0064341","article-title":"Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis","volume":"8","author":"Huaux","year":"2013","journal-title":"PLoS ONE"},{"key":"2021042700290910900_BIO053116C36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000149783","article-title":"Cl transport in complemented CF bronchial epithelial cells correlates with CFTR mRNA expression levels","volume":"22","author":"Illek","year":"2008","journal-title":"Cell. Physiol. Biochem."},{"key":"2021042700290910900_BIO053116C37","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2021042700290910900_BIO053116C38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1159\/000265129","article-title":"Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease","volume":"29","author":"Leier","year":"2012","journal-title":"Cell. Physiol. Biochem."},{"issue":"Suppl. 1","key":"2021042700290910900_BIO053116C39","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1038\/sj.ijir.3901207","article-title":"Tissue expression, distribution, and regulation of PDE5","volume":"16","author":"Lin","year":"2004","journal-title":"Int. J. Impot. Res."},{"key":"2021042700290910900_BIO053116C40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1527-3466.2006.00261.x","article-title":"The many faces of H89: a review","volume":"24","author":"Lochner","year":"2006","journal-title":"Cardiovasc. Drug Rev."},{"key":"2021042700290910900_BIO053116C41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1164\/rccm.200703-344OC","article-title":"Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis","volume":"177","author":"Lubamba","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021042700290910900_BIO053116C42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1183\/09031936.00013510","article-title":"Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice","volume":"37","author":"Lubamba","year":"2011","journal-title":"Eur. Respir. J."},{"key":"2021042700290910900_BIO053116C43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jcf.2012.03.003","article-title":"Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice","volume":"11","author":"Lubamba","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"2021042700290910900_BIO053116C44","doi-asserted-by":"crossref","first-page":"21592","DOI":"10.1016\/S0021-9258(20)80582-1","article-title":"The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells","volume":"268","author":"Lukacs","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2021042700290910900_BIO053116C45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1042\/bj3280353","article-title":"Constitutive internalization of cystic fibrosis transmembrane conductance regulator occurs via clathrin-dependent endocytosis and is regulated by protein phosphorylation","volume":"328","author":"Lukacs","year":"1997","journal-title":"Biochem. J."},{"key":"2021042700290910900_BIO053116C46","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/0140-6736(93)90641-S","article-title":"Evolution of nitric oxide","volume":"341","author":"Moncada","year":"1993","journal-title":"Lancet"},{"key":"2021042700290910900_BIO053116C47","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1042\/CS20160749","article-title":"Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms","volume":"131","author":"Noel","year":"2017","journal-title":"Clin. Sci."},{"key":"2021042700290910900_BIO053116C48","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1021\/ac00180a014","article-title":"Enzyme immunoassays of adenosine cyclic 3\u2032,5\u2032-monophosphate and guanosine cyclic 3\u2019,5\u2019-monophosphate using acetylcholinesterase","volume":"61","author":"Pradelles","year":"1989","journal-title":"Anal. Chem."},{"key":"2021042700290910900_BIO053116C49","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"2021042700290910900_BIO053116C50","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.leu.2404139","article-title":"Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL","volume":"20","author":"Ross","year":"2006","journal-title":"Leukemia"},{"key":"2021042700290910900_BIO053116C51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0163-7258(00)00051-6","article-title":"Cyclic nucleotide analogs as biochemical tools and prospective drugs","volume":"87","author":"Schwede","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"2021042700290910900_BIO053116C52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jcf.2014.10.006","article-title":"Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease","volume":"14","author":"Taylor-Cousar","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"2021042700290910900_BIO053116C53","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2021042700290910900_BIO053116C54","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S1569-1993(18)30325-4","article-title":"P028 Riociguat for the treatment of adult Phe508del homozygous cystic fibrosis: efficacy data from the Phase II Rio-CF study","volume":"17","author":"Taylor-Cousar","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"2021042700290910900_BIO053116C55","doi-asserted-by":"publisher","first-page":"35825","DOI":"10.1074\/jbc.M110.131623","article-title":"The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis","volume":"285","author":"Thibodeau","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2021042700290910900_BIO053116C56","doi-asserted-by":"crossref","first-page":"14964","DOI":"10.1016\/S0021-9258(18)77210-4","article-title":"Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase","volume":"265","author":"Thomas","year":"1990","journal-title":"J. Biol. Chem."},{"key":"2021042700290910900_BIO053116C57","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1074\/jbc.271.12.7025","article-title":"N-terminal myristoylation is required for membrane localization of cGMP-dependent protein kinase type II","volume":"271","author":"Vaandrager","year":"1996","journal-title":"J. Biol. Chem."},{"key":"2021042700290910900_BIO053116C58","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1073\/pnas.95.4.1466","article-title":"Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl- channel activation","volume":"95","author":"Vaandrager","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042700290910900_BIO053116C59","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042700290910900_BIO053116C60","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042700290910900_BIO053116C61","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2021042700290910900_BIO053116C62","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1124\/mol.106.029926","article-title":"Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones","volume":"71","author":"Wang","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"2021042700290910900_BIO053116C63","doi-asserted-by":"publisher","first-page":"014022","DOI":"10.1117\/1.3083439","article-title":"Resolution in the ApoTome and the confocal laser scanning microscope: comparison","volume":"14","author":"Weigel","year":"2009","journal-title":"J. Biomed. Opt."},{"key":"2021042700290910900_BIO053116C64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1165\/rcmb.2005-0161OC","article-title":"Long-term cultures of polarized airway epithelial cells from patients with cystic fibrosis","volume":"34","author":"Wiszniewski","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2021042700290910900_BIO053116C65","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1161\/CIRCRESAHA.106.144501","article-title":"cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology","volume":"100","author":"Zaccolo","year":"2007","journal-title":"Circ. Res."}],"container-title":["Biology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1242\/bio.053116","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.logists.com\/bio\/bio\/article-pdf\/doi\/10.1242\/bio.053116\/1836187\/bio053116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.logists.com\/bio\/bio\/article-pdf\/doi\/10.1242\/bio.053116\/2062976\/bio_053116v1.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/journals.logists.com\/bio\/bio\/article-pdf\/doi\/10.1242\/bio.053116\/2062976\/bio_053116v1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T23:39:45Z","timestamp":1621381185000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/bio\/article\/doi\/10.1242\/bio.053116\/266433\/Vardenafil-increases-intracellular-accumulation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":65,"URL":"https:\/\/doi.org\/10.1242\/bio.053116","relation":{},"ISSN":["2046-6390"],"issn-type":[{"type":"electronic","value":"2046-6390"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"article-number":"bio.053116"}}